The article by LaCasce et al entitled “Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)” (J Clin Oncol 10.1200/JCO.22.00947) was ...

The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission tomography (PET)-driven de-escalation strategy after two cycles of bleomycin, etoposide, ...

The global Positron Emission Tomography (PET) market is set to witness a growth rate of 5% in the next 5 years. Growing prevalence of chronic diseases; technological advancements in ...

Positron Emission Tomography (PET) Scanners Global Market Overview 2021-2023 & 2024-2030 - ResearchAndMarkets.com February 17, 2025 10:25 AM Eastern Standard Time ...

Learn how PET study shows safe, targeted brain delivery of intranasal insulin, a critical step for future Alzheimer’s ...

A Mayo Clinic study confirmed the accuracy of a new FDA-approved blood test for early detection of Alzheimer's disease.

Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain ...

Traditionally, the diagnosis of Alzheimer’s disease has been based on informant interviews and clinical assessments of memory, cognition, behaviour, and mood. To increase diagnostic confidence, ...

Jubilant Radiopharma Announces Investment of $50 million (USD) to Expand Positron Emission Tomography (PET) Manufacturing Network June 24, 2024 02:15 PM Eastern Daylight Time ...

SAN DIEGO, June 25, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment ...